Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
SchizophreniaSchizophrenic DisordersPsychotic DisordersDementia Praecox
Interventions
DRUG

Paliperidone ER

1.5 to 12 mg tablet once daily for 6 months

Trial Locations (53)

Unknown

Cerritos

San Diego

Santa Ana

Middletown

Washington D.C.

Jacksonville

Coeur d'Alene

Chicago

Lake Charles

Shreveport

Las Vegas

Cincinnati

Cleveland

Oklahoma City

Antwerp

Sofia

Tallinn

Tartu

Viljandi

Hus

Kellokoski

Chennai

Hyderabad

Mangalore

Varanasi

Gdansk

Lódź

Poznan

Sosnowiec

Torun

Warsaw

Bucharest

Ekaterinburg Na

Kazan'

Moscow

Moscow Russia

Nizhny Novgorod

Saint Petersburg

Saratov

Smolensk Region N/A

Stavropol Na

Tomsk Na

Yaroslavl

Cheonan

Gyeonggi-do

Kyunggi-Do

Seoul

Dnipro

Hlevakha

Kharkiv

Kiev

Odesa

Simferopol

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT00488319 - Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia. | Biotech Hunter | Biotech Hunter